Achieving more frequent and longer dialysis for the majority: Wearable dialysis and implantable artificial kidney devices

Kidney International

Volumn 84, Issue 2, 2013, Pages 256-264

  Fissell, William H ^a   Roy, Shuvo ^b   Davenport, Andrew ^c  

^a VANDERBILT UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Continuous dialysis; Daily dialysis sorbent; Implantable dialysis; Middle molecule; Protein bound toxins; Wearable dialysis

Indexed keywords

BICARBONATE; PHOSPHATE BINDING AGENT; VITAMIN D DERIVATIVE;

ARTIFICIAL KIDNEY; ARTIFICIAL WEARABLE AMBULATORY KIDNEY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTINUOUS RENAL REPLACEMENT THERAPY; CONTINUOUS WEARABLE HRMODIALYSIS DEVICE; DIALYSATE; DIALYSIS; EQUIPMENT DESIGN; HEALTH CARE COST; HEMODIALYSIS MACHINE; HUMAN; IMPLANTABLE ARTIFICIAL KIDNEY DEVICE; KIDNEY FUNCTION; LONG TERM SURVIVAL; NONHUMAN; PERITONEAL DIALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RENAL ASSIST DEVICE; REVIEW; TREATMENT DURATION; UROLOGICAL EQUIPMENT; VASCULAR ACCESS; WEARABLE DIALYSIS;

EQUIPMENT DESIGN; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEYS, ARTIFICIAL; MINIATURIZATION; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; QUALITY OF LIFE; RENAL DIALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84881150393     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.466     Document Type: Review

References (39)

1. Davenport A, Gura V, Ronco C et al. A wearable hemodialysis device for patients with end-stage renal failure: a pilot study. Lancet 2007; 370: 2005-2010. (Pubitemid 350236337)
2. Bomar JB, Decherd JF, Hlavinka DJ et al. The elucidation of maximum efficiency-minimum cost peritoneal dialysis protocols. Trans Am Soc Artif Intern Organs 1974; 20A: 120-129.
3. Moncrief JW, Popovich RP, Nolph KD. The history and current status of continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1990; 16: 579-584.
4. Ronco C, Fecondini L. The Vicenza wearable artificial kidney for peritoneal dialysis (ViWAK PD). Blood Purif 2007; 25: 383-388. (Pubitemid 47450571)
5. Ronco C, Davenport A, Gura V. A wearable artificial kidney: dream or reality? Nat Clin Pract Nephrol 2008; 4: 604-605.
6. Davenport A. Role of dialysis technology in the removal of uraemic toxins. Hemodial Int 2011; 15(Suppl 1): S49-S53.
7. Lee DBN, Roberts M. A peritoneal based automated wearable artificial kidney. Clin Exper Nephrol 2008; 12: 171-180.
8. Maroni BJ, Steinman TI, Mitch WE. A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int 1985; 27: 58-65. (Pubitemid 15130686)
9. Roberts M, Lee DBN. Wearable artificial kidneys. A peritoneal dialysis approach. Dial Transplant 2006; 36: 780-782.
10. Gura V, Davenport A, Beizai M et al. Beta 2-microglobulin and phosphate clearances using a wearable artificial kidney: a pilot study. Am J Kidney Dis 2009; 54: 104-111.
11. Gura V, Ronco C, Davenport A. The wearable artificial kidney, why and how: from holy grail to reality. Semin Dial 2009; 22: 13-17.
12. Gura V, Ronco C, Nalesso F et al. A wearable haemofilter: first human study of slow continuous ambulatory ultrafiltration. Kidney Int 2008; 74: 497-502. (Pubitemid 351186292)
13. Davenport A. Anticoagulation for continuous renal replacement therapy. Contrib Nephrol 2004; 144: 228-238.
14. Cafazzo JA, Leonard K, Easty AC et al. Patient-perceived barriers to the adoption of nocturnal home haemodialysis. Clin J Am Soc Nephrol 2009; 4: 784-789.
15. Sergeyeva O̧, Gorodetskaya I, Ramos R et al. Frequent Hemodialysis Network Trials Group. Challenges to enrollment and randomization of the Frequent Hemodialysis Network (FHN) Daily Trial. J Nephrol 2012; 25: 302-309.
16. Carson RC, Juszczak M, Davenport A et al. Is maximum conservative management an equivalent treatment option to dialysis for elderly patients with significant comorbid disease? Clin J Am Soc Nephrol 2009; 4: 1611-1619.
17. Caplin B, Kumar S, Davenport A. Patients' perspective of haemodialysisassociated symptoms. Nephrol Dial Transplant 2011; 26: 2656-2663.
18. Melvin ME, Fissell WH, Roy S et al. Silicon induces minimal thromboinflammatory response during 28-Day intravascular implant testing. ASAIO J 2010; 56: 344-348.
19. Vernon K, Peasegood J, Riddell A et al. Dialyzers designed to increase internal filtration do not result in significantly increased platelet activation and thrombin generation. Nephron Clin Pract 2010; 117: c403-c408.
20. Hofmann CL, Fissell WH. Middle-molecule clearance at 20 and 35 ml/kg/h in continuous veno-venous haemodiafiltration. Blood Purif 2010; 29: 259-263.
21. Messer J, Mulcahy B, Fissell WH. Middle-molecule clearance in CRRT: invitro convection, diffusion, and dialyzer area. ASAIO J 2009; 55: 224-226.
22. Holland NB, Qiu Y, Ruegsegger M et al. Biomimetic engineering of nonadhesive glycocalyx-like surfaces using oligosaccharide surfactant polymers. Nature 1998; 392: 799-801. (Pubitemid 28225316)
23. Vacheethasanee K, Marchant RE. Surfactant polymers designed to suppress bacterial (Staphylococcus epidermidis) adhesion on biomaterials. J Biomed Mat Res 2000; 50: 302-312. (Pubitemid 30180722)
24. Blantz RC, Gabbai FB, Peterson O et al. Water and protein permeability is regulated by the glomerular epithelial slit diaphragm. J Am Soc Nephrol 1994; 4: 1957-1964. (Pubitemid 24977002)
25. Rodewald R, Karnovsky MJ. Porous substructure of the glomerular slit diaphragm in the rat and mouse. J Cell Biol 1974; 60: 423-433.
26. Zeman LJ, Zydney AL. Microfiltration and Ultrafiltration. Marcel Dekker: New York, 1996, pp 180-253.
27. Davenport A. Membrane designs and composition for haemodialysis, haemofiltration and haemodialfiltration: past, present and future. Minerva Urol Nefrol 2010; 62: 29-40.
28. Fissell WH, Dubnisheva A, Eldridge AN et al. High-performance silicon nanopore hemofiltration membranes. J Memb Sci 2009; 326: 58-63.
29. Kanani DM, Fissell WH, Roy S et al. Permeability-selectivity analysis for ultrafiltration: Effect of pore geometry. J Memb Sci 2010; 349: 405-410.
30. Fissell WH, Kimball J, MacKay SM et al. The role of a bioengineered artificial kidney in renal failure. Ann N Y Acad Sci 2001; 944: 284-295. (Pubitemid 34053315)
31. Humes HD, Fissell WH, Weitzel WF et al. Metabolic replacement of kidney function in uremic animals with a bioartificial kidney containing human cells. Am J Kidney Dis 2002; 39: 1078-1087. (Pubitemid 34454228)
32. Tumlin J, Wali R, Williams W et al. Efficacy and safety of renal tubule cell therapy for acute renal failure. J Am Soc Nephrol 2008; 19: 1034-1040.
33. Humes HD, Buffington DA, MacKay SM et al. Replacement of renal function in uremic animals with a tissue-engineered kidney. Nat Biotechnol 1999; 17: 451-455. (Pubitemid 29217896)
34. Humes HD, Weitzel WF, Bartlett RH et al. Initial clinical results of the bioartificial kidney containing human cells in ICU patients with acute renal failure. Kidney Int 2004; 66: 1578-1588. (Pubitemid 39298393)
35. Fissell WH, Manley S, Westover A et al. Differentiated growth of human renal tubule cells on thin-film and nanostructured materials. ASAIO J 2006; 52: 221-227. (Pubitemid 44314869)
36. Ferrell N, Desai RR, Fleischman AJ et al. A microfluidic bioreactor with integrated transepithelial electrical resistance (TEER) measurement electrodes for evaluation of renal epithelial cells. Biotechnol Bioengin 2010; 107: 707-716.
37. Ferrell N, Ricci KB, Groszek JJ et al. Albumin handling by renal tubular epithelial cells in a microfluidic bioreactor. Biotechnol Bioengin 2011; 109: 797-803.
38. Burg MB, Orloff J. Control of fluid absorption in the renal proximal tubule. J Clin Invest 1968; 47: 2016-2024.
39. Kokko JP, Burg MB, Orloff J. Characteristics of NaCl and water transport in the renal proximal tubule. J Clin Invest 1971; 50: 69-76.